Illinois Municipal Retirement Fund grew its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 5.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 321,286 shares of the biopharmaceutical company’s stock after buying an additional 15,533 shares during the quarter. Gilead Sciences accounts for 0.5% of Illinois Municipal Retirement Fund’s holdings, making the stock its 22nd largest holding. Illinois Municipal Retirement Fund’s holdings in Gilead Sciences were worth $47,888,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Persistent Asset Partners Ltd purchased a new position in shares of Gilead Sciences during the second quarter valued at $25,000. Kimelman & Baird LLC bought a new stake in shares of Gilead Sciences in the second quarter valued at about $25,000. PFS Partners LLC raised its holdings in shares of Gilead Sciences by 101.1% in the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 96 shares in the last quarter. Laurel Wealth Advisors LLC purchased a new stake in Gilead Sciences in the third quarter worth about $29,000. Finally, Wiser Advisor Group LLC purchased a new stake in Gilead Sciences in the second quarter worth about $30,000. Institutional investors own 83.67% of the company’s stock.
Insiders Place Their Bets
In other news, EVP Keeley Cain Wettan sold 3,399 shares of the firm’s stock in a transaction on Friday, November 6th. The stock was sold at an average price of $164.11, for a total value of $557,809.89. Following the completion of the sale, the executive vice president owned 5,360 shares of the company’s stock, valued at $879,629.60. This trade represents a 38.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total value of $468,660.00. Following the transaction, the insider owned 113,684 shares in the company, valued at approximately $17,759,714.48. This trade represents a 2.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 242,709 shares of company stock worth $39,503,427. 0.30% of the stock is currently owned by company insiders.
Gilead Sciences Stock Performance
NASDAQ:GILD opened at $170.87 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $116.88 and a 52 week high of $176.58. The firm has a 50 day moving average of $154.00 and a 200 day moving average of $141.34. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The company had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. During the same period last year, the firm earned $2.47 earnings per share. Gilead Sciences’s revenue was up 6.8% compared to the same quarter last year. As a group, research analysts predict that Gilead Sciences, Inc. will post -1.07 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is currently -103.80%.
Wall Street Analyst Weigh In
Several research analysts have issued reports on GILD shares. BMO Capital Markets reiterated an “outperform” rating and set a $184.00 target price on shares of Gilead Sciences in a report on Friday, October 30th. JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $170.00 to $190.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Citigroup boosted their price target on shares of Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a report on Friday, October 30th. Scotiabank upped their price target on shares of Gilead Sciences from $177.00 to $200.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 30th. Finally, Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. Twenty-three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $170.15.
View Our Latest Research Report on Gilead Sciences
Key Stories Impacting Gilead Sciences
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Recent coverage highlights improving growth across Gilead’s business and strong recent results. Its latest reported quarter beat consensus on both earnings and revenue, with revenue up 6.8% year over year. This supports the positive investment case behind the stock’s advance toward a 52-week high. Article: Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?
- Positive Sentiment: Analysts have recently raised price targets, including JPMorgan and Wells Fargo to $190, and maintained positive ratings—potential support for investor sentiment. Gilead Sciences analyst and stock information
- Neutral Sentiment: Gilead partner Xilio Therapeutics said it expects to deliver an option data package for its investigational cancer drug efarindodekin alfa to Gilead in the first half of 2027. Any value to Gilead depends on future data and potential payments; the update does not establish a near-term financial benefit. Xilio Therapeutics pipeline update
- Negative Sentiment: An executive vice president sold 3,399 shares, reducing his holdings by about 39%. The sale was made under a pre-arranged trading plan, which may limit its significance as a signal about the company’s outlook. Gilead Sciences insider-trading report
- Negative Sentiment: Vir, a competitor in hepatitis D, reported positive results for its experimental treatment. The news could raise competitive concerns, though the supplied report does not indicate an immediate impact on Gilead’s business. Vir rival advances hepatitis D treatment
Gilead Sciences Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Featured Articles
- Five stocks we like better than Gilead Sciences
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
